Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 33


N-terminal pro-B-type natriuretic peptide, tricuspid jet flow velocity, and death in adults with sickle cell disease.

Schimmel M, van Beers EJ, van Tuijn CF, Nur E, Rijneveld AW, Mac Gillavry MR, Brandjes DP, Schnog JJ, Biemond BJ; CURAMA study group.

Am J Hematol. 2015 Apr;90(4):E75-6. doi: 10.1002/ajh.23944. Epub 2015 Feb 2. No abstract available.


Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.

Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C; RE-COVER II Trial Investigators.

Circulation. 2014 Feb 18;129(7):764-72. doi: 10.1161/CIRCULATIONAHA.113.004450. Epub 2013 Dec 16.


Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators.

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.


Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab.

van Hasselt JG, Schellens JH, Mac Gillavry MR, Beijnen JH, Huitema AD.

Pharm Res. 2012 Dec;29(12):3499-511. doi: 10.1007/s11095-012-0845-y. Epub 2012 Aug 21.


A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.

Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, Schellens JH, Karlsson MO, Huitema AD.

J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):347-63. doi: 10.1007/s10928-010-9164-2. Epub 2010 Jul 23.


Contraindications for anticoagulation in older patients with atrial fibrillation; a narrative review.

Tulner LR, Kuper IM, van Campen JP, Mac Gillavry MR, Kwa VI, Koks CH, Beijnen JH, Brandjes DP.

Curr Drug Saf. 2010 Jul 2;5(3):223-33. Review.


Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study.

Tulner LR, Van Campen JP, Kuper IM, Gijsen GJ, Koks CH, Mac Gillavry MR, van Tinteren H, Beijnen JH, Brandjes DP.

Drugs Aging. 2010 Jan 1;27(1):39-50. doi: 10.2165/11319540-000000000-00000. Review.


Treatment of hypertension in an elderly outpatient population in the Netherlands.

Tulner LR, Kuper IM, van Campen JP, Koks CH, Mac Gillavry MR, Beijnen JH, Brandjes DP.

Am J Geriatr Pharmacother. 2009 Aug;7(4):204-9. doi: 10.1016/j.amjopharm.2009.08.002.


Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension.

van Beers EJ, Nur E, Schaefer-Prokop CM, Mac Gillavry MR, van Esser JW, Brandjes DP, Kappers-Klunne MC, Duits AJ, Muskiet FA, Schnog JJ, Biemond BJ; CURAMA Study Group.

Am J Hematol. 2008 Nov;83(11):850-4. doi: 10.1002/ajh.21272.


Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension.

Landburg PP, Teerlink T, van Beers EJ, Muskiet FA, Kappers-Klunne MC, van Esser JW, Mac Gillavry MR, Biemond BJ, Brandjes DP, Duits AJ, Schnog JJ; CURAMA study group.

Haematologica. 2008 Sep;93(9):1410-2. doi: 10.3324/haematol.12928. Epub 2008 Jul 18. No abstract available.


Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice.

van Beers EJ, van Tuijn CF, Mac Gillavry MR, van der Giessen A, Schnog JJ, Biemond BJ; CURAMA study group.

Haematologica. 2008 May;93(5):757-60. doi: 10.3324/haematol.12152. Epub 2008 Mar 26.


Large and medium-sized pulmonary artery obstruction does not play a role of primary importance in the etiology of sickle-cell disease-associated pulmonary hypertension.

van Beers EJ, van Eck-Smit BL, Mac Gillavry MR, van Tuijn CF, van Esser JW, Brandjes DP, Kappers-Klunne MC, Duits AJ, Biemond BJ, Schnog JJ; CURAMA Study Group.

Chest. 2008 Mar;133(3):646-52. doi: 10.1378/chest.07-1694. Epub 2008 Jan 15.


Dengue disease severity in Indonesian children: an evaluation of the World Health Organization classification system.

Setiati TE, Mairuhu AT, Koraka P, Supriatna M, Mac Gillavry MR, Brandjes DP, Osterhaus AD, van der Meer JW, van Gorp EC, Soemantri A.

BMC Infect Dis. 2007 Mar 26;7:22.


ADAMTS13 activity in sickle cell disease.

Schnog JJ, Kremer Hovinga JA, Krieg S, Akin S, Lämmle B, Brandjes DP, Mac Gillavry MR, Muskiet FD, Duits AJ; CURAMA Study Group.

Am J Hematol. 2006 Jul;81(7):492-8.


Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism.

ten Wolde M, Söhne M, Quak E, Mac Gillavry MR, Büller HR.

Arch Intern Med. 2004 Aug 9-23;164(15):1685-9. Review.


Observer variability in the assessment of clinical probability in patients with suspected pulmonary embolism.

Leclercq MG, Kruip MJ, Mac Gillavry MR, Van Marwijk Kooy M, Büller HR.

J Thromb Haemost. 2004 Jul;2(7):1204-6. No abstract available.


Protein C and S and inflammation in sickle cell disease.

Schnog JB, Mac Gillavry MR, van Zanten AP, Meijers JC, Rojer RA, Duits AJ, ten Cate H, Brandjes DP.

Am J Hematol. 2004 May;76(1):26-32.


Does the location of deep venous thrombosis of the leg determine the risk of the post-thrombotic syndrome?

Bank I, Mac Gillavry MR, Brandjes DP, Büller HR.

J Thromb Haemost. 2003 Sep;1(9):2058-9. No abstract available.


Oral contraceptives and inherited thrombophilia: a gene-environment interaction with a risk of venous thrombosis?

Mac Gillavry MR, Prins MH.

Semin Thromb Hemost. 2003 Apr;29(2):219-26. Review.


Travel and the risk of symptomatic venous thromboembolism.

ten Wolde M, Kraaijenhagen RA, Schiereck J, Hagen PJ, Mathijssen JJ, Mac Gillavry MR, Koopman MM, Büller HR.

Thromb Haemost. 2003 Mar;89(3):499-505.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk